- Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
-
Kim M, Kim S, Yim J, Keam B, Kim TM, Jeon YK, Kim DW, Heo DS
- KMID: 2547788
- Cancer Res Treat.
- 2023 Oct;55(4):1134-1143.
- doi: 10.4143/crt.2023.311
Purpose In patients with epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC), EGFR tyrosine kinase inhibitors (TKIs) improve response rate and survival. However, most patients eventually develop resistance.... -
- CITED
-
- Close
- SHARE
-
- Close
- Sublobar Resection versus Stereotactic Body Radiation Therapy for Clinical Stage I Non–Small Cell Lung Cancer: A Study Using Data from the Korean Nationwide Lung Cancer Registry
-
Yun J, Cho JH, Hong TH, Yang K, Ahn YC, Kim HK, Korean Association for Lung Cancer, Korea Central Cancer Registry
- KMID: 2547791
- Cancer Res Treat.
- 2023 Oct;55(4):1171-1180.
- doi: 10.4143/crt.2022.1581
Purpose Stereotactic body radiotherapy (SBRT) had been increasingly recognized as a favorable alternative to surgical resection in patients with high risk for surgery. This study compared survival outcomes between sublobar... -
- CITED
-
- Close
- SHARE
-
- Close
- Identification of novel potential drugs and miRNAs biomarkers in lung cancer based on gene co-expression network analysis
-
Hajipour S, Hosseini SM, Irani S, Tavallaie M
- KMID: 2547072
- Genomics Inform.
- 2023 Sep;21(3):e38.
- doi: 10.5808/gi.23039
Non–small cell lung cancer (NSCLC) is an important cause of cancer-associated deaths worldwide. Therefore, the exact molecular mechanisms of NSCLC are unidentified. The present investigation aims to identify the miRNAs... -
- CITED
-
- Close
- SHARE
-
- Close
- EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study
-
Gu W, Zhang H, Lu Y, Li M, Yang S, Liang J, Ye Z, Li Z, He M, Shi X, Wang F, You D, Gu W, Feng W
- KMID: 2544165
- Cancer Res Treat.
- 2023 Jul;55(3):841-850.
- doi: 10.4143/crt.2022.1438
Purpose We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations. Materials and... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion
-
Kim YJ, Ji WJ, Lee JC, Chun SM, Choi CM
- KMID: 2534178
- Cancer Res Treat.
- 2022 Oct;54(4):985-995.
- doi: 10.4143/crt.2021.857
Purpose This study was to evaluate anti-tumor efficacy of osimertinib in patients positive for acquired epidermal growth factor receptor (EGFR) T790M mutation in liquid biopsy using plasma, bronchoalveolar lavage fluid (BALF)... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer
-
Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, Kim YM, Jung JS, Kang Y, Ji W, Choi MG, Lee JC, Rho JK, Choi CM
- KMID: 2534180
- Cancer Res Treat.
- 2022 Oct;54(4):1005-1016.
- doi: 10.4143/crt.2021.986
Purpose The aim of this study is to evaluate the safety and efficacy of ex vivo activated and expanded natural killer (NK) cell therapy (SNK01) plus pembrolizumab in a randomized... -
- CITED
-
- Close
- SHARE
-
- Close
- The Value of the Illness-Death Model for Predicting Outcomes in Patients with Non–Small Cell Lung Cancer
-
Chae KJ, Choi H, Jeong WG, Kim J
- KMID: 2534179
- Cancer Res Treat.
- 2022 Oct;54(4):996-1004.
- doi: 10.4143/crt.2021.902
Purpose The illness-death model (IDM) is a comprehensive approach to evaluate the relationship between relapse and death. This study aimed to illustrate the value of the IDM for identifying risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer
-
Yoon S, Yang H, Ryu HM, Lee E, Jo Y, Seo S, Kim D, Lee CH, Kim W, Jung KH, Park SR, Choi EK, Kim SW, Park KS, Lee DH
- KMID: 2531323
- Cancer Res Treat.
- 2022 Jul;54(3):767-781.
- doi: 10.4143/crt.2021.651
Purpose Heat shock protein-90 (HSP90) remains an important cancer target because of its involvement in multiple oncogenic protein pathways and biologic processes. Although many HSP90 inhibitors have been tested in the... -
- CITED
-
- Close
- SHARE
-
- Close
- Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
-
Rivera-Concepcion J, Uprety D, Adjei AA
- KMID: 2528202
- Cancer Res Treat.
- 2022 Apr;54(2):315-329.
- doi: 10.4143/crt.2022.078
Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage NSCLC. Increasing... -
- CITED
-
- Close
- SHARE
-
- Close
- miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37
-
Kim MS, Kim SH, Yang SH, Kim MS
- KMID: 2528214
- Cancer Res Treat.
- 2022 Apr;54(2):445-457.
- doi: 10.4143/crt.2021.622
Purpose With the identification of epidermal growth factor receptor (EGFR) mutations in non–small cell lung cancer (NSCLC) cells, EGFR–tyrosine kinase inhibitors (TKIs) are being used widely as the first-line of treatment... -
- CITED
-
- Close
- SHARE
-
- Close
- TTF1-positive SMARCA4/BRG1 deficient lung adenocarcinoma
-
Mehta A, Diwan H, Bansal D, Gupta M
- KMID: 2524230
- J Pathol Transl Med.
- 2022 Jan;56(1):53-56.
- doi: 10.4132/jptm.2021.09.16
SMARCA4/BRG1-deficient lung adenocarcinoma (SD-LUAD) is being recognized as a distinct subtype based on subtle differences in its clinical, morphological, and immunophenotypic attributes compared to other non–small cell lung carcinomas. We... -
- CITED
-
- Close
- SHARE
-
- Close
- Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer
-
Lee C, Kim M, Kim DW, Kim TM, Kim S, Im SW, Jeon YK, Keam B, Ku JL, Heo DS
- KMID: 2524595
- Cancer Res Treat.
- 2022 Jan;54(1):140-149.
- doi: 10.4143/crt.2021.385
Purpose Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare and poorly understood oncogenic mutation in non–small cell lung cancer (NSCLC). We aimed to investigate the acquired resistance... -
- CITED
-
- Close
- SHARE
-
- Close
- Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
-
Garg G, Prasad KT, Singh N, Gupta P, Muthu V, Das A, Bal A
- KMID: 2522441
- J Pathol Transl Med.
- 2021 Nov;55(6):398-405.
- doi: 10.4132/jptm.2021.08.08
Background: Data on the prevalence of programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in non–small cell lung cancer (NSCLC) and their clinical significance in Indian patients are limited.... -
- CITED
-
- Close
- SHARE
-
- Close
- Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer
-
Yoo YJ, Kim SS, Song SY, Kim JH, Ahn SD, Lee Sw, Yoon SM, Kim YS, Park Jh, Jung J, Choi EK
- KMID: 2520456
- Radiat Oncol J.
- 2021 Sep;39(3):202-209.
- doi: 10.3857/roj.2021.00416
Purpose: To investigate the safety and efficacy of hypofractionated radiation therapy (HFRT) in patients with non-small cell lung cancer who are unfit for surgery or stereotactic body radiation therapy (SBRT)... -
- CITED
-
- Close
- SHARE
-
- Close
- SMARCA4/BRG1 protein-deficient thoracic tumors dictate re-examination of small biopsy reporting in non–small cell lung cancer
-
Mehta A, Bansal D, Tripathi R, Jajodia A
- KMID: 2520169
- J Pathol Transl Med.
- 2021 Sep;55(5):307-316.
- doi: 10.4132/jptm.2021.05.11
Background: SMARCA4/BRG1 protein–deficient lung adenocarcinomas and thoracic sarcoma are recently described entities that lack distinctive histological features, transcription termination factor 1 (TTF1) reactivity, and actionable driver mutations. The current diagnostic... -
- CITED
-
- Close
- SHARE
-
- Close
- Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer
-
Shin H, Noh JM, Pyo H, Ahn YC, Oh D
- KMID: 2514511
- Radiat Oncol J.
- 2021 Mar;39(1):24-32.
- doi: 10.3857/roj.2020.01074
Purpose: This study aimed to evaluate the clinical outcomes and toxicities of salvage proton beam therapy (PBT) in patients with locoregional recurrent non-small cell lung cancer (NSCLC). Materials and Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Active Treatment Improves Overall Survival in Extremely Older Non–Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
-
Lee SY, Hong YK, Ji W, Lee JC, Choi CM, Korean Association for Lung Cancer, Korea Central Cancer Registry
- KMID: 2510652
- Cancer Res Treat.
- 2021 Jan;53(1):104-111.
- doi: 10.4143/crt.2020.894
Purpose As the aging of society progresses, the proportion of extremely older lung cancer patients has also increased; However, studies of these patients with non–small cell lung cancer are limited. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
-
Park CK, Cho HJ, Choi YD, Oh IJ, Kim YC
- KMID: 2510651
- Cancer Res Treat.
- 2021 Jan;53(1):93-103.
- doi: 10.4143/crt.2020.459
Purpose Osimertinib is a potent, irreversible third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for both EGFR-activating and T790M resistant mutation. The treatment efficacy of osimertinib was assessed in... -
- CITED
-
- Close
- SHARE
-
- Close
- An Unusual Case of Metastatic Non-Small Cell Lung Cancer Misidentified as Anaplastic Thyroid Cancer
-
Ko HM, Kim JR
- KMID: 2509203
- Int J Thyroidol.
- 2020 Nov;13(2):170-174.
- doi: 10.11106/ijt.2020.13.2.170
Metastases from other organs to the thyroid are considered to be extremely rare. Among thyroid malignancies, anaplastic thyroid cancer exhibits similar features to a number of other cancers and can... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
-
Shin J, Chung JH, Kim SH, Lee KS, Suh KJ, Lee JY, Kim JW, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS
- KMID: 2454300
- Cancer Res Treat.
- 2019 Jul;51(3):1086-1097.
- doi: 10.4143/crt.2018.537
PURPOSE: Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression... -
- CITED
-
- Close
- SHARE
-
- Close
